Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02863328 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 822
- Enrollment target
- 20
- Study locations
NCT02863328 is a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 822 participants, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT02863328, a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 822 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
Conditions Studied
Interventions
- DRUG semaglutide
- DRUG empagliflozin
Study Locations (20)
Florida
- Novo Nordisk Investigational Site - Bradenton
- Novo Nordisk Investigational Site - Jacksonville
- Novo Nordisk Investigational Site - Jacksonville
- Novo Nordisk Investigational Site - Jacksonville
- Novo Nordisk Investigational Site - Miami
- Novo Nordisk Investigational Site - Miami Lakes
- Novo Nordisk Investigational Site - Orlando
- Novo Nordisk Investigational Site - Oviedo
California
- Novo Nordisk Investigational Site - Encino
- Novo Nordisk Investigational Site - La Mesa
- Novo Nordisk Investigational Site - Northridge
- Novo Nordisk Investigational Site - Palm Springs
- Novo Nordisk Investigational Site - Poway
- Novo Nordisk Investigational Site - Riverside
- Novo Nordisk Investigational Site - Spring Valley
Georgia
- Novo Nordisk Investigational Site - Atlanta
- Novo Nordisk Investigational Site - Perry
Alabama
- Novo Nordisk Investigational Site - Tuscumbia
Idaho
- Novo Nordisk Investigational Site - Meridian
Illinois
- Novo Nordisk Investigational Site - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2016-08-10 |
| Est. Completion | 2018-03-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02863328
The ClinicalTrials.gov registry entry for NCT02863328 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 822 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (82% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which semaglutide is the first listed.
NCT02863328 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02863328 about?
NCT02863328 is a clinical study titled "Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus". This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT02863328?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 822 participants. The study started on 2016-08-10. Estimated completion is 2018-03-08.
What conditions does trial NCT02863328 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes.
What interventions are being tested in trial NCT02863328?
The interventions under investigation include: semaglutide (DRUG), empagliflozin (DRUG).
Who is sponsoring clinical trial NCT02863328?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02863328 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.